Advanced Filters
noise

Lake Oswego, Oregon Clinical Trials

A listing of Lake Oswego, Oregon clinical trials actively recruiting patient volunteers.

Found 564 clinical trials
L Linda Stork, MD

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for …

13 - 39 years of age All Phase 1
V Vamsi Kota, MD

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or …

18 years of age All Phase 2
K Kimberly Chun, BS

Total Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study

Traditionally, general anesthesia is maintained with inhalational anesthesia (GAS), but there is a gap in knowledge regarding whether intravenous anesthesia (IV) can prevent deleterious postoperative outcomes in the geriatric surgical population. The goal of this clinical trial is to determine whether intravenous anesthesia (IV) leads to a decreased incidence of …

70 - 110 years of age All Phase 4
S Saurabh S Thosar, PhD

Sleep and Circadian Mechanisms in Hypertension

This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).

25 - 64 years of age All Phase N/A
A Alison Stopeck, MD

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer

A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)

years of age All Phase 2
C Cancer Connect

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of …

18 years of age Female Phase 2
C Chris Catlin

Sleep for Health Study on the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk

This study tests whether providing cognitive behavioral therapy for insomnia (CBT-I) to people with prediabetes results in a reduction in glucose levels compared to a patient education control program.

22 - 79 years of age All Phase N/A
C Christen Lauder

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

The purpose of this dose escalation study is to evaluate the safety profile of escalating doses and dose schedules of NXP900.

18 years of age All Phase 1
R Rongchu Chen

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

To evaluate CAN1012(Selective TLR7 agonist) when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

18 - 80 years of age All Phase 1

Maternal Stress on Human Milk and Infant Outcomes

The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.

18 - 50 years of age Female Phase N/A

Simplify language using AI